Progress of chimeric antigen receptor T cell immunotherapy in B cell hematologic malignancies:reports from the 56th American Society of Hematology annual meeting
10.3760/cma.j.issn.1009-9921.2015.02.002
- VernacularTitle:嵌合型抗原受体T细胞治疗技术在B细胞肿瘤中的研究进展:第56届美国血液学会年会报道
- Author:
Biping DENG
;
Hongxing LIU
;
Chunrong TONG
- Publication Type:Journal Article
- Keywords:
Chimeric antigen receptor T cell;
CD19;
B cell hematologic malignancies;
American Society of Hematology annual meeting
- From:
Journal of Leukemia & Lymphoma
2015;24(2):71-73,78
- CountryChina
- Language:Chinese
-
Abstract:
Chimeric antigen receptor T cell (CAR-T) therapy has shown promising perspective in clinical trails of B cell hematologic malignancies.Meanwhile,this therapy still need to be further improved in the following aspects:design of CAR-T,cancer antigens selection,T cells origin,and clinical application strategy.CAR-T immunotherapy is one of hot topics in the 56th American Society of Hematology (ASH) annual meeting.Some breakthroughs have been reported in both basic research and clinical trails.
